secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0000882095-21-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance
--------------------------------------------------------------------------------

- Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).
- GAAP diluted EPS $1.21 (vs. loss of $2.66); non-GAAP diluted EPS $1.87 (+68%).
- Veklury sales $829M; HIV sales $3.9B (-2%); Biktarvy up 24%; HCV up 23%.
- FY2021 guidance: product sales $24.4-25.0B; Veklury $2.7-3.1B (prev $2.0-3.0B); non-GAAP EPS $6.90-7.25.
- Quarterly dividend $0.71 payable Sep 29, record Sep 15; pipeline updates include lenacapavir NDA filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/0000882095-21-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/gild-20210729.htm
  HTML page:      https://secwatch.observer/filing/0000882095-21-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer